Marc Banjak
Förmögenhet: 31 750 $ per 2026-08-31
Förmögenhet: 31 750 $ per 2026-08-31
Marc A. Banjak is currently Chief Legal Officer at iBio, Inc. since 2025.
Formerly, Mr. Banjak was General Counsel at Istari Oncology, Inc., General Counsel at Dova Pharmaceuticals, Inc. from 2017 to 2021, and a Member of The Colorado Bar Association.
Education includes undergraduate studies at Franklin & Marshall College and graduate studies at Sturm College of Law.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IBIO, INC. 0,07 % | 2026-03-26 | 25 000 ( 0,07 % ) | 31 750 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| IBIO, INC. | Generell Rådgivare | - |
| Företag | Position | Slut |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Generell Rådgivare | 2021-04-01 |
The Colorado Bar Association | Företagsledare/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Revisor | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån